SEN-JAM Pharmaceutical

The Pharma for the people, people

Print
Follow Claim My Business
Form C
View on Wefunder
Security Type
Convertible Note
Categories
Technology, Alcohol, Infrastructure, Community & Lifestyle, Consumer Goods & Products, Healthcare & Medical, Other, Financial Services
Min Investment
$250
Location
Huntington, NY
Offering Date
October 22, 2022
Expected Close Date
April 30, 2025
Target Raise
$150.00K-$5.00M
No. Investors
1
Security Price
$1
Valuation
$69,979,019
Website
sen-jam.com
Number of Employees
5
Cash
$331,764
Revenue
$0
Short Term Debt
$1,111,512
Cost of Goods
$0
Long Term Debt
$1,756,114
Net Income
$-4,355,706

Company Description

Creating highly accessible, affordable, safe drugs that work
Lead indications:
oral COVID-19 therapeutic, opioid withdrawal, & alcohol hangover prevention
Annual US market opportunity: $17B
Current valuation (rNPV): COVID-19: $55M, hangover prevention: $120M, and opioid withdrawal" $261M
COVID-19 therapeutic clinical trial with Duke-NUS begins Dec., leading to valuation inflection point
Female founder is clinical pharmacist
Team of mission-oriented, like-minded individuals focused on worldwide healthcare
Global IP includes 25 patents and patents pending

Key Deal Facts

Creating highly accessible, affordable, safe drugs that work
Lead indications: oral COVID-19 therapeutic, opioid withdrawal, & alcohol hangover prevention
Annual US market opportunity: $17B
Current valuation (rNPV): COVID-19: $55M, hangover prevention: $120M, and opioid withdrawal" $261M
COVID-19 therapeutic clinical trial with Duke-NUS begins Dec., leading to valuation inflection point
Founder is clinical pharmacist
Team of mission-oriented, like-minded individuals focused on worldwide healthcare
Global IP includes 25 patents and patents pending
Amount Raised : $3,077,362
Reveal the Score by Voting
＿
0
ⓘ
Business Idea
ⓘ
Business Traction
ⓘ
Management Team
ⓘ
Valuation

Security Description

A convertible security is a security that can be converted into another security, typically equity in the next round of financing.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment